Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8865971 | 0.86 | KCNH2 (0.42) | SIRT2CES1MAPT | |
| SCHEMBL1414901 | 0.84 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2MAPTL3MBTL1 | |
| SCHEMBL9489847 | 0.84 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL1735234 | 0.83 | CYP11B1 (0.37) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL10457151 | 0.82 | HPGD (0.39) | SIRT2CYP11B1CYP11B2CES1CES2 | |
| SCHEMBL5682164 | 0.82 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL670904 | 0.82 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2LMNAL3MBTL1 | |
| SCHEMBL1602656 | 0.81 | SIRT2 (0.38) | SIRT2LMNAL3MBTL1 | |
| SCHEMBL30962386 | 0.81 | ADA (0.41) | SIRT2LMNAMAPTL3MBTL1 | |
| SCHEMBL31298440 | 0.81 | SIRT2 (0.37) | SIRT2CYP11B1CYP11B2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735438-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735438-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735438-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20110077274-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077274-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077274-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7902247-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902247-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902247-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2240453-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009089132-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089132-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077274-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB3, ADRB2 | SIRT2 3570/4885CYP11B1 201/4885CYP11B2 209/4885 |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB3, ADRB2 | SIRT2 3498/4885CYP11B1 180/4885CYP11B2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.